hacked by trenggalek6etar
— JATIM4U —
Jangene_Cakep – Panataran – 0x1999 – 0xIDiot – Unlucky – Mr.Optimuz_Root
— JATIM4U —
Jangene_Cakep – Panataran – 0x1999 – 0xIDiot – Unlucky – Mr.Optimuz_Root
— JATIM4U —
Jangene_Cakep – Panataran – 0x1999 – 0xIDiot – Unlucky – Mr.Optimuz_Root

YWO NEWS | COMMODITIES | DEEP DIVE / ANALYSIS
Brent crude for September delivery rose 2.54% to breach $90 per barrel on Monday, while WTI for August delivery climbed 2.29% to $84.38, as American forces completed a ninth consecutive night of strikes against Iranian targets, CNBC’s Lee Ying Shan reported. According to CNBC, market participants were reacting to a combination of geopolitical developments, including the confirmation of three U.S. service members killed, the recovery of unidentified remains near an Iranian attack site in Jordan, and continuing concerns surrounding the Strait of Hormuz — through which roughly one-fifth of global oil supply passes.
The U.S. Central Command confirmed in a statement posted to X that its strikes have targeted Iranian coastal surveillance and air defense systems, maritime assets, and missile and drone storage facilities. CENTCOM also struck Islamic Revolutionary Guard Corps units linked to the July 17 attack on U.S. personnel in Jordan — the same attack that left two dead, one missing, and now a third service member confirmed killed, per CNBC.
“The strikes will continue degrading Iranian military capabilities used to attack commercial vessels and civilian mariners transiting the Strait of Hormuz,” CENTCOM said.
That statement is relevant to energy markets because the Strait of Hormuz is a key global shipping route for crude oil exports from several major producing countries. The Strait of Hormuz handles traffic from Kuwait, Iraq, the UAE, and Iran itself. Any sustained disruption affecting shipping through the Strait of Hormuz could influence global crude supply and market pricing.
David Roche of Quantum Strategy, cited in CNBC’s coverage, put a number on the supply-side risk. In a note published Monday, Roche wrote that Gulf exports are already dwindling and that at the current rate of depletion, “oil inventories get tight in September and even the U.S. gets stressed.”
Roche’s $95–$105 target range for Brent is the only analyst forecast in the sourced material — and it carries a specific inventory logic rather than just a geopolitical premium call. Roche’s assessment suggests that inventory levels could become tighter by September if current trends continue, although this remains an analyst view rather than an established outcome.
Roche also noted what he called “TACO pressure” on President Trump — a reference to domestic political constraints on how long and how intensively the U.S. campaign can continue before energy costs become a policy problem at home.
| Asset | Move | Level | Source |
|---|---|---|---|
| Brent Crude (Sep, BZ=F) | +2.54% | >$90/bbl | CNBC |
| WTI Crude (Aug, CL=F) | +2.29% | $84.38/bbl | CNBC |
The Investing.com morning note flagged oil and rising yields as compounding pressures across global markets — the inflationary read-through is the secondary story here. A sustained move above $90 in Brent flows through to headline CPI in economies that haven’t fully de-linked from pump prices, and it lands at a moment when several major central banks are still managing the last mile of disinflation.
Energy equities — tracked via XLE and USO on U.S. exchanges —have historically been sensitive to movements in crude oil prices. . The relationship between crude and integrated energy names is textbook: upstream producers see margin expansion directly off the commodity price. Whether that offset materialises depends on how durable the geopolitical premium proves to be. A premium built on conflict risk can unwind fast — and often does.
Markets have priced Hormuz closure risk before without the canal ever actually closing. That history means the current move has to be evaluated against the possibility that nine nights of U.S. strikes represents the peak of escalation rather than the beginning of a longer campaign. CENTCOM’s stated objective — degrading Iranian military capability — is finite in scope. If Iranian maritime threat capacity is assessed as sufficiently reduced, the military rationale for continued strikes diminishes.
That scenario — a de-escalation after the ninth consecutive night, rather than a tenth — could reduce the geopolitical risk premium currently reflected in energy prices. . The Investing.com framing of “rising oil” as a headwind for risk assets more broadly suggests the market is already aware that at some price, the energy bid becomes a macro problem rather than a sector opportunity.
Supply tightness through September, per Roche’s inventory thesis, may provide a floor independent of the conflict premium. But inventory data — most recently from the EIA — will be the next hard read on whether that thesis is holding.
Risk Disclaimer: Trading CFDs involves substantial risk and may not be suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You may lose some or all of your invested capital. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Past performance is not a reliable indicator of future results. This article is provided for general informational and educational purposes only and does not constitute financial, investment, legal, tax, or trading advice, nor a recommendation, solicitation, or offer to buy or sell any financial instrument. Any commentary or analysis is intended solely to provide context to the publicly available information referenced in the article and should not be interpreted as proprietary research, independent investment research, financial advice, or a recommendation to engage in any investment or trading activity.

YWO NEWS | EQUITIES | DEEP DIVE / ANALYSIS
Five of the largest US banks reported second-quarter earnings before Tuesday’s open in an unusually compressed morning, with JPMorgan Chase posting a 41% jump in net income to $21.2 billion and Bank of America reporting revenue of $31.7 billion, up 15% from a year earlier, CNBC’s Hugh Son and Laya Neelakandan reported. The releases — covering JPMorgan (JPM), Bank of America (BAC), Wells Fargo (WFC), Goldman Sachs, and Citigroup were all published before Tuesday’s market open.
JPMorgan’s reported results included one-time gains that affected the year-on-year comparison. . According to CNBC reported, excluding approximately $5.6 billion of gains on Visa and other one-time items, net income growth was approximately 13%. , JPM shares were up less than 1% on the print and then fell roughly 2% in premarket trading.
The standout line item at JPMorgan was equities trading. Revenue came in at $6 billion, up 86% year-over-year, beating the StreetAccount consensus by $2.11 billion, Hugh Son at CNBC noted. Fixed income was a slight miss, printing at $6.1 billion against a $6.22 billion estimate, with lower commodities revenue the cited drag.
Investment banking fees added to the story: $3.3 billion, up 30% year-over-year, roughly half a billion dollars above the consensus of $2.82 billion. JPMorgan specifically called out “particularly strong performance” in equity underwriting fees — language that points directly to the SpaceX IPO, which drove surging deal fees across Wall Street in Q2, CNBC reported.
CEO Jamie Dimon leaned into the breadth of the result. “Performance was strong across the Firm, and revenue in each line of business hit a new record,” Dimon said in the earnings statement, as reported by Hugh Son.
Dimon also addressed the macro backdrop. “The U.S. economy has demonstrated notable resiliency this year, with stronger business investment and hiring,” he said, attributing the strength to “AI-driven capital investment, fiscal stimulus and the benefits of more efficient regulation,” per the earnings statement cited by CNBC’s Leslie Picker.
Bank of America’s headline numbers beat on both lines — $1.21 EPS versus $1.13 expected, and $31.7 billion in revenue against a $30.72 billion Wall Street estimate, according to CNBC, with analyst expectations compiled by LSEG.
Investment banking was among the strongest-performing business lines. . Fees came in at $2.1 billion, up 50% from the year-ago period, against a StreetAccount consensus of just $1.86 billion, Laya Neelakandan reported for CNBC. Net interest income landed at $16.2 billion, up 9%, driven by global markets activity and higher loan and deposit balances, essentially in line with the StreetAccount consensus of $16.23 billion.
The 50% surge in investment banking fees at BofA — alongside JPMorgan’s 30% jump in the same category — reflects the same SpaceX-driven underwriting windfall, with commercial lending also showing what CNBC described as signs of a turnaround.
Strong trading desks and fee windfalls from a single high-profile IPO do not, on their own, resolve the two questions markets were most focused on heading into this morning: credit quality and net interest income trajectory, CNBC noted. BofA’s NII came in close to consensus, but the full picture on consumer credit health and loan loss provisions across all five banks was still emerging from the earnings calls as of Tuesday morning.
JPMorgan shares traded lower in premarket trading despite the reported earnings. . CNBC noted that analysts were also considering the impact of excluding one-time gains when evaluating the results. . The conference call with analysts, scheduled for 8:30 a.m. ET, was the next forum for Dimon and CFO Jeremy Barnum to address NII guidance and credit-quality commentary, CNBC reported.
Wells Fargo beat on both top and bottom lines in Q2 as well, per the same live coverage, though the detailed line items were still being reported as of the published update.
| Bank | Revenue | EPS | Key Beat |
|---|---|---|---|
| JPMorgan (JPM) | — | — | Equities trading +86% to $6bn; IB fees $3.3bn vs $2.82bn est. |
| Bank of America (BAC) | $31.7bn vs $30.72bn est. | $1.21 vs $1.13 est. | IB fees $2.1bn (+50% YoY) vs $1.86bn est. |
| Wells Fargo (WFC) | Beat | Beat | Top and bottom line beat confirmed |
Sources: CNBC, StreetAccount, LSEG consensus
Goldman Sachs and Citigroup results were also due Tuesday morning as part of the same reporting sweep. Goldman’s numbers were anticipated to reflect the same SpaceX underwriting tailwind — the IPO drove surging fees for Goldman and Morgan Stanley specifically, CNBC reported.
The five-bank simultaneous release is itself an unusual event. The simultaneous publication of results from several large banks meant investors received multiple earnings announcements before the market opened.
Risk Disclaimer: Trading CFDs involves substantial risk and may not be suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You may lose some or all of your invested capital. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Past performance is not a reliable indicator of future results. This article is provided for general informational and educational purposes only and does not constitute financial, investment, legal, tax, or trading advice, nor a recommendation, solicitation, or offer to buy or sell any financial instrument.

YWO NEWS | COMMODITIES | DEEP DIVE / ANALYSIS
WTI crude futures for August delivery soared 3.34% to $80.75 a barrel by 6:24 a.m. ET on Tuesday, while international benchmark Brent for September delivery climbed 4.45% to $87.01, extending gains after Brent had already advanced 9.6% in the prior session, CNBC’s Lee Ying Shan reported. The dual catalyst: President Trump’s announcement that the U.S. will levy fees on all vessels transiting the Strait of Hormuz — “at the rate of 20% on all cargo shipped” — and a simultaneous move to reinstate a blockade of Iranian ports near the strait.
The blockade wasn’t just a threat left dangling. U.S. Central Command confirmed it would take effect at 4 p.m. ET on Tuesday, per CNBC. The confirmation by U.S. Central Command provided additional operational detail regarding the announced measures, according to CNBC.
Roughly one-fifth of global oil supplies transited the Strait of Hormuz before the U.S. and Israel launched strikes on Iran on February 28, CNBC reported. Shipping traffic had slumped after Iran began targeting vessels in the waterway in early March, then started to recover following an interim agreement between Washington and Tehran. Tuesday’s announcements put that recovery squarely in doubt.
Trump framed the toll via Truth Social, describing the United States as the “guardian” of the strait — a framing that simultaneously justified the fee and signalled Washington’s willingness to control the chokepoint militarily if challenged. The 20% levy on all cargo, combined with the reinstated port blockade, contributed to increased attention on geopolitical risks affecting global energy markets.
.
Citi warned in a report published early Tuesday that Trump’s proposal “materially raises the risk of further military escalation,” CNBC reported. The bank went further, writing that “the possibility that the Iranian regime walks away from the MoU until after the mid-term US elections has also risen, a scenario which would most likely see higher for longer oil prices.”
| Asset | Move | Level | Timeframe |
|---|---|---|---|
| WTI (Aug. delivery) | +3.34% | $80.75/bbl | 6:24 a.m. ET, 14 Jul |
| Brent (Sep. delivery) | +4.45% | $87.01/bbl | 6:24 a.m. ET, 14 Jul |
| Brent (prior session) | +9.6% | — | 13 Jul session |
Source: CNBC
Across the two sessions, Brent recorded a cumulative gain of approximately 13.05%, according to CNBC market data.
The source material is careful with its language, and so is the market. The Iran ceasefire has “showed signs of collapse,” per the Investing.com report — not a confirmed termination. The distinction reflects continuing uncertainty regarding the geopolitical situation. .
Previous developments were accompanied by changes in shipping activity and oil prices, according to CNBC. Brent crude remains above the levels seen before the events of 28 February, reflecting the continued market focus on geopolitical developments affecting global energy markets. Market participants will continue to monitor developments relating to the memorandum of understanding (MoU) and any official announcements that may affect regional stability. Citi also noted the potential for further developments depending on the direction of negotiations, according to CNBC.
Market participants are also awaiting further details regarding the implementation of the announced measures. As one analyst cited by CNBC observed, “announcement is not implementation.” At the time of publication, the operational and legal framework for the proposed 20% cargo levy on transit through the Strait of Hormuz had not been fully detailed. According to the available information, matters such as implementation, potential exemptions and the applicable legal framework had not yet been clarified.
The EIA’s weekly petroleum supply report, which covers crude inventories, refinery runs, and product stocks, is a recurring focal point for crude pricing — the schedule is available at the EIA. The report will provide updated information on U.S. crude inventories and supply conditions.
CME settlement data is published daily and provides information on crude futures pricing — CME Group data daily. The 4 p.m. ET Tuesday blockade implementation window, per USCENTRALCOM’s confirmation cited by CNBC, is the immediate operational marker.
Risk Disclaimer: Trading CFDs involves substantial risk and may not be suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You may lose some or all of your invested capital. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Past performance is not a reliable indicator of future results. This article is provided for general informational and educational purposes only and does not constitute financial, investment, legal, tax, or trading advice, nor a recommendation, solicitation, or offer to buy or sell any financial instrument.

YWO NEWS | MACRO | DEEP DIVE / ANALYSIS
US Treasury yields rose across the curve on Tuesday morning as traders raised their bets on Federal Reserve interest rate hikes, with the 10-year yield sitting at 4.622% by 6:02 a.m. ET, up more than 1 basis point on the session, CNBC’s Hugh Leask reported. The session is carrying two events that have drawn the market’s full attention: the June inflation print, due later Tuesday, and Fed Chairman Kevin Warsh’s debut testimony before the House Financial Services Committee.
On Monday, Treasury yields rose after the 10-year yield jumped 4 basis points and the 2-year surged more than 6 basis points after President Donald Trump announced plans to blockade Iranian ports and impose fees of 20% on cargo passing through the Strait of Hormuz, according to CNBC. Tuesday’s yield movements were more limited — Tuesday’s 2-year yield rose more than 1 basis point to 4.277%, and the 30-year added nearly 1 basis point to 5.105% — but the direction is unchanged.
Oil prices rose following developments relating to the Strait of Hormuz, while Treasury yields also increased, according to CNBC. . West Texas Intermediate futures were last 3.2% higher at $80.66 a barrel, while Brent crude jumped 4.3% to $86.90, CNBC reported. Higher oil prices may influence inflation expectations, and market participants continue to monitor their potential impact on interest-rate expectations.
The CME FedWatch tool now shows traders pricing a 39% probability of a July 29 rate hike, up from 26.7% a week ago, according to CNBC. Expectations for two hikes by April next year have been gathering pace alongside the oil move.
| Asset | Level / Move | Source |
|---|---|---|
| US 10-year yield | 4.622% (+>1 bp, Tue) | CNBC |
| US 2-year yield | 4.277% (+>1 bp, Tue) | CNBC |
| US 30-year yield | 5.105% (+~1 bp, Tue) | CNBC |
| WTI crude | $80.66 (+3.2%) | CNBC |
| Brent crude | $86.90 (+4.3%) | CNBC |
| July 29 hike probability | 39% (vs. 26.7% one week ago) | CME FedWatch |
Another focus for market participants is Fed Chair Kevin Warsh’s testimony. . Tuesday marks his first appearance before Congress as Fed chair, with a House Financial Services Committee appearance scheduled for later in the day and a Senate Banking Committee session on Wednesday, CNBC reported.As this is Mr. Warsh’s first congressional testimony as Fed Chair, market participants may monitor his comments on monetary policy and economic conditions.
The testimony coincides with the release of the June CPI report. . If the June CPI print, also due Tuesday, comes in above the consensus forecast of 3.8% year-on-year — down from May’s 4.2% — Warsh will face a live, data-hot interrogation from the committee. Core CPI is expected to hold at 2.9% year-on-year, per consensus figures cited by CNBC. A surprise to the upside on either measure would arrive while Warsh is mid-testimony.
Market expectations may continue to evolve following the release of the June CPI report and Fed Chair Kevin Warsh’s congressional testimony. According to the consensus figures cited by CNBC, headline CPI is expected at 3.8% year-on-year, compared with 4.2% in May, while core CPI is expected to remain at 2.9%. Market participants will assess the published data alongside the Fed Chair’s comments for any indications regarding the economic outlook and monetary policy. Developments in energy markets and geopolitical events may also continue to influence inflation expectations over time.
Risk Disclaimer: Trading CFDs involves substantial risk and may not be suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You may lose some or all of your invested capital. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Past performance is not a reliable indicator of future results. This article is provided for general informational and educational purposes only and does not constitute financial, investment, legal, tax, or trading advice, nor a recommendation, solicitation, or offer to buy or sell any financial instrument.

YWO NEWS | EQUITIES | DEEP DIVE / ANALYSIS
AstraZeneca’s London-listed shares fell 9.1% on Thursday — the worst single-session drop since March 2020 — after the British drugmaker announced that its late-stage heart disease trial for Wainua failed to meet its primary endpoint, CNBC’s Elsa Ohlen reported. NYSE-listed AZN shares were down 8.4% in premarket trading.
The drug, Wainua, was being tested in patients with transthyretin-mediated amyloid cardiomyopathy — ATTR-CM — a rare, life-threatening condition in which misfolded proteins accumulate in the heart muscle, stiffening it and ultimately leading to heart failure. Over 140 weeks, Wainua added on top of standard care did not show a statistically meaningful reduction in deaths and recurrent heart-related emergencies compared to placebo, AstraZeneca confirmed in a press release Thursday morning. Roughly half a million people live with the condition globally.
According to AstraZeneca and analysts cited by CNBC, attention has focused on aspects of the study design when assessing the trial outcome. In the study cohort, 57% of patients were already receiving a stabilizer treatment at baseline — a drug that prevents the protein from misfolding in the first place. A further 24% initiated a stabilizer during the trial. According to the reported trial results, Wainua did not demonstrate a statistically significant improvement in the primary endpoint when added to standard care.
For patients who had not taken a stabilizer at baseline, Wainua did show a “nominally significant” risk reduction in deaths and heart events versus placebo, AstraZeneca said. Although the subgroup findings did not alter the primary endpoint, AstraZeneca reported them as part of the overall study results. .
Jefferies analysts, cited by CNBC, were direct about the reputational dimension:
“AstraZeneca is meant to be able to have ‘exceptionally good trial design ability,’ and to see the trial fail on design flaws like the percentage of patients on stabilizers, will hit the company’s credibility.”
Jefferies attributed significance to the study design when discussing the trial outcome. . Over 14 years as CEO, AstraZeneca built its standing partly on the premise that it ran tight trials, especially in oncology. A failure attributed to patient-cohort design hands critics a structural argument, not just a statistical one.
Jefferies did not move to jeopardise AstraZeneca’s $80 billion sales target by 2030, but modelled for $2.5 billion less in risk-adjusted sales for Wainua specifically, CNBC reported. The analysts flagged that AstraZeneca “had been very confident around the primary endpoint and the ability to hit in combination use” — which makes the miss harder to absorb than a trial where management had already flagged uncertainty.
“The bigger issue is probably a degree of credibility loss with management being very confident in the trial’s ability to hit the primary endpoint as well as an ability to show utility on top of background therapy,” Jefferies said.
Citi, also cited by CNBC, went further on the commercial path: it said it was unlikely AstraZeneca could file for additional ATTR-CM approvals for Wainua given the primary endpoint miss, pointing to Alnylam Pharmaceuticals’ existing approved treatment for the same indication as the competitive barrier.
AstraZeneca confirmed that Wainua’s existing licence was unaffected. The drug is already approved for conditions where misfolded proteins cause nerve damage rather than cardiac damage, and is sold in Europe under the brand name Wainzua. Thursday’s failure applies specifically to the cardiac-use expansion, not the underlying approval.
The collateral damage ran directly to Ionis Pharmaceuticals, which is co-developing Wainua in the United States. IONS shares fell 20% in premarket trading Thursday, CNBC reported — a move roughly twice as severe as AstraZeneca’s own decline, reflecting the drug’s proportionally larger importance to Ionis’s pipeline.
In contrast, Alnylam Pharmaceuticals shares rose 17% in premarket trading on the same news. Alnylam already has a treatment for ATTR-CM on the market, and the Wainua failure removes a competing therapy before it could challenge that position. The three-way split — AZN down 9%, IONS down 20%, ALNY up 17% — reflecting differing market reactions following the announcement.
Jefferies noted that the stock may not recover its footing until AstraZeneca’s next major catalyst — the AVANZAR trial for cancer — delivers a result, CNBC reported. The analysts said they “would not be surprised seeing people pause for now until the catalyst path is clearer.” That framing positions the current dislocation as a holding pattern, not necessarily a structural re-rating — though the credibility question Jefferies raised may take more than one clean readout to fully address.
AstraZeneca has not announced a revised timeline or filing plan for Wainua in the cardiac indication following Thursday’s announcement. The company’s press release confirmed only that the existing licence remains intact and that it believes the results “support greater scientific” understanding — a phrase that was cut off in the available source text, CNBC noted the full statement was published Thursday morning.
| Asset | Move | Context |
|---|---|---|
| AZN (London) | −9.1% | Worst day since March 2020 |
| AZN (NYSE, premarket) | −8.4% | Per CNBC premarket data |
| IONS (premarket) | −20% | Co-developer of Wainua |
| ALNY (premarket) | +17% | Competitor with existing ATTR-CM drug on market |
Sources: CNBC
Jefferies noted that it continues to model AstraZeneca’s broader long-term revenue target despite reducing its risk-adjusted sales estimate for Wainua. The analysts also highlighted management credibility as a factor they believe market participants may continue to monitor following the trial results.
Risk Disclaimer: Trading CFDs involves substantial risk and may not be suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You may lose some or all of your invested capital. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Past performance is not a reliable indicator of future results. This article is provided for general informational and educational purposes only and does not constitute financial, investment, legal, tax, or trading advice, nor a recommendation, solicitation, or offer to buy or sell any financial instrument.